Mindset Pharma says its next-generation psilocybin compounds could change the paradigm of microdosing by limiting the psychedelic effect.
Drug discovery and development company focused on creating next-generation psychedelic medicines for neurological and psychiatric disorders, Mindset Pharma, recently announced that candidates from its Family 3 compounds, comprised of long-acting psilocybin side-chain restricted analogues, have demonstrated extended duration of action and decreased effect size at the 5-HT2A receptor.
The compounds decreased action on the receptor limits the compounds psychedelic effect, which the company says would enable the therapeutic benefits of psychedelics whilst limiting the potential to elicit a psychedelic experience.
Next-generation compounds
The company says its Family 3 compounds of next-generation psilocybin analogues are engineered to deliver the therapeutic benefits associated with microdosing across a range of doses while limiting hallucinogenic liability.
It notes that the results indicate a “potentially significant improvement in the sustained efficacy and safety profile of current microdosing practices.”
Mindset CEO, James Lanthier, said: “The preclinical results for our long-acting psilocybin analogues have meaningful implications for psychedelic-based therapy at low doses.
“These findings indicate the potential for us to change the paradigm of microdosing therapies by delivering the therapeutic benefits of psychedelics with limited potential to elicit a hallucinogenic experience at a wide range of effective doses.”
Mindset has run a battery of specialised in vitro and in vivo tests on its patent-pending novel compounds to select the optimal candidates for progressing towards human clinical trials.
“In vivo results indicated that our Family 3 compounds demonstrated approximately 1/10th the effect size as psilocybin on behavioural measures of 5-HT2A activity in the mouse and are predicted to have extended duration of action consistent with once a day or once every other day dosing,” added Mindset CSO Joseph Araujo.
“We plan to continue testing our low-dose Family 3 NCEs in translational preclinical animal models to elucidate potential cognitive enhancing effects of our compounds.”
